Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

Kelly, who made several key hires at the CDRH and helped negotiate the last user fee agreement, announced his departure in a ...

The agency formulated its advice to manufacturers after coordinating with the CDC and Defense Department. An advisory meeting ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a ...

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...